SHPHY (Sihuan Pharmaceutical Holdings Group) Beta: N/A (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHPHY Sihuan Pharmaceutical Holdings Group Ltd SHPHY
56 GF Score
Price $4.36
GF Value $6.15
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sihuan Pharmaceutical Holdings Group Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-08-16), Sihuan Pharmaceutical Holdings Group's Beta is Not available.

Sihuan Pharmaceutical Holdings Group  (OTCPK:SHPHY) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Sihuan Pharmaceutical Holdings Group Beta Related Terms

Sihuan Pharmaceutical Holdings Group Beta Historical Data

* Premium members only.

The historical data trend for Sihuan Pharmaceutical Holdings Group's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sihuan Pharmaceutical Holdings Group Beta Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHPHY
56GF Score
Sihuan Pharmaceutical Holdings Group Ltd SHPHY
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sihuan Pharmaceutical Holdings Group Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Sihuan Pharmaceutical Holdings Group (SHPHY) Overvalued in 2026?

Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued. The current stock price of $4.36 is trading 29.2% below its estimated GF Value™ of $6.15. GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.

Key valuation signals for SHPHY:

  • Beta: N/A
  • GF Value™: $6.15 vs. price of $4.36 (29.2% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the SHPHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sihuan Pharmaceutical Holdings Group Business Description

Other Exchanges 00460:Hong KongTEL1:Germany
Address 1 Harbour Road, Convention Plaza, Room 4905, Office Tower, Wanchai, HKG
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
56GF Score

Get the complete analysis for SHPHY

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.36
Price
$6.15
GF Value